Valproate and bone loss: ITRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells

Heidi R. Fuller, Nguyen Thi Man, Le Thanh Lam, Vladimir A. Shamanin, Elliot Androphy, Glenn E. Morris

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Valproate is commonly used as an anticonvulsant and mood stabilizer, but its long-term side-effects can include bone loss. As a histone deacetylase (HDAC) inhibitor, valproate has also been considered for treatment of spinal muscular atrophy (SMA). Using iTRAQ labeling technology, followed by two-dimensional liquid chromatography and mass spectrometry analysis, a quantitative comparison of the proteome of an SMA cell line, with and without valproate treatment, was performed. The most striking change was a reduction in collagens I and VI, while over 1000 other proteins remained unchanged. The collagen I alpha-chain precursor was also reduced by more than 50% suggesting that valproate affects collagen I synthesis. The collagen-binding glycoprotein, osteonectin (SPARC, BM-40) was one of the few other proteins that were significantly reduced by valproate treatment. Collagen I is the main protein component of bone matrix and osteonectin has a major role in bone development, so the results suggest a possible molecular mechanism for bone loss following long-term exposure to valproate. SMA patients may already suffer bone weakness as a result of SMN1 gene deletion, so further bone loss would be undesirable.

Original languageEnglish (US)
Pages (from-to)4228-4233
Number of pages6
JournalJournal of Proteome Research
Volume9
Issue number8
DOIs
StatePublished - Aug 6 2010
Externally publishedYes

Fingerprint

Osteonectin
Spinal Muscular Atrophy
Valproic Acid
Proteomics
Bone
Collagen
Bone and Bones
Bone Matrix
Proteins
Histone Deacetylase Inhibitors
Bone Development
Liquid chromatography
Gene Deletion
Proteome
Liquid Chromatography
Anticonvulsants
Labeling
Mass spectrometry
Mass Spectrometry
Glycoproteins

Keywords

  • bone
  • collagen
  • histone deacetylase inhibitor
  • iTRAQ
  • osteonectin
  • SMN
  • spinal muscular atrophy
  • Valproate
  • Valproate and bone loss

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Valproate and bone loss : ITRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells. / Fuller, Heidi R.; Man, Nguyen Thi; Lam, Le Thanh; Shamanin, Vladimir A.; Androphy, Elliot; Morris, Glenn E.

In: Journal of Proteome Research, Vol. 9, No. 8, 06.08.2010, p. 4228-4233.

Research output: Contribution to journalArticle

Fuller, Heidi R. ; Man, Nguyen Thi ; Lam, Le Thanh ; Shamanin, Vladimir A. ; Androphy, Elliot ; Morris, Glenn E. / Valproate and bone loss : ITRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells. In: Journal of Proteome Research. 2010 ; Vol. 9, No. 8. pp. 4228-4233.
@article{d3852ee15aa84ae2918957780b6539e8,
title = "Valproate and bone loss: ITRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells",
abstract = "Valproate is commonly used as an anticonvulsant and mood stabilizer, but its long-term side-effects can include bone loss. As a histone deacetylase (HDAC) inhibitor, valproate has also been considered for treatment of spinal muscular atrophy (SMA). Using iTRAQ labeling technology, followed by two-dimensional liquid chromatography and mass spectrometry analysis, a quantitative comparison of the proteome of an SMA cell line, with and without valproate treatment, was performed. The most striking change was a reduction in collagens I and VI, while over 1000 other proteins remained unchanged. The collagen I alpha-chain precursor was also reduced by more than 50{\%} suggesting that valproate affects collagen I synthesis. The collagen-binding glycoprotein, osteonectin (SPARC, BM-40) was one of the few other proteins that were significantly reduced by valproate treatment. Collagen I is the main protein component of bone matrix and osteonectin has a major role in bone development, so the results suggest a possible molecular mechanism for bone loss following long-term exposure to valproate. SMA patients may already suffer bone weakness as a result of SMN1 gene deletion, so further bone loss would be undesirable.",
keywords = "bone, collagen, histone deacetylase inhibitor, iTRAQ, osteonectin, SMN, spinal muscular atrophy, Valproate, Valproate and bone loss",
author = "Fuller, {Heidi R.} and Man, {Nguyen Thi} and Lam, {Le Thanh} and Shamanin, {Vladimir A.} and Elliot Androphy and Morris, {Glenn E.}",
year = "2010",
month = "8",
day = "6",
doi = "10.1021/pr1005263",
language = "English (US)",
volume = "9",
pages = "4228--4233",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Valproate and bone loss

T2 - ITRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells

AU - Fuller, Heidi R.

AU - Man, Nguyen Thi

AU - Lam, Le Thanh

AU - Shamanin, Vladimir A.

AU - Androphy, Elliot

AU - Morris, Glenn E.

PY - 2010/8/6

Y1 - 2010/8/6

N2 - Valproate is commonly used as an anticonvulsant and mood stabilizer, but its long-term side-effects can include bone loss. As a histone deacetylase (HDAC) inhibitor, valproate has also been considered for treatment of spinal muscular atrophy (SMA). Using iTRAQ labeling technology, followed by two-dimensional liquid chromatography and mass spectrometry analysis, a quantitative comparison of the proteome of an SMA cell line, with and without valproate treatment, was performed. The most striking change was a reduction in collagens I and VI, while over 1000 other proteins remained unchanged. The collagen I alpha-chain precursor was also reduced by more than 50% suggesting that valproate affects collagen I synthesis. The collagen-binding glycoprotein, osteonectin (SPARC, BM-40) was one of the few other proteins that were significantly reduced by valproate treatment. Collagen I is the main protein component of bone matrix and osteonectin has a major role in bone development, so the results suggest a possible molecular mechanism for bone loss following long-term exposure to valproate. SMA patients may already suffer bone weakness as a result of SMN1 gene deletion, so further bone loss would be undesirable.

AB - Valproate is commonly used as an anticonvulsant and mood stabilizer, but its long-term side-effects can include bone loss. As a histone deacetylase (HDAC) inhibitor, valproate has also been considered for treatment of spinal muscular atrophy (SMA). Using iTRAQ labeling technology, followed by two-dimensional liquid chromatography and mass spectrometry analysis, a quantitative comparison of the proteome of an SMA cell line, with and without valproate treatment, was performed. The most striking change was a reduction in collagens I and VI, while over 1000 other proteins remained unchanged. The collagen I alpha-chain precursor was also reduced by more than 50% suggesting that valproate affects collagen I synthesis. The collagen-binding glycoprotein, osteonectin (SPARC, BM-40) was one of the few other proteins that were significantly reduced by valproate treatment. Collagen I is the main protein component of bone matrix and osteonectin has a major role in bone development, so the results suggest a possible molecular mechanism for bone loss following long-term exposure to valproate. SMA patients may already suffer bone weakness as a result of SMN1 gene deletion, so further bone loss would be undesirable.

KW - bone

KW - collagen

KW - histone deacetylase inhibitor

KW - iTRAQ

KW - osteonectin

KW - SMN

KW - spinal muscular atrophy

KW - Valproate

KW - Valproate and bone loss

UR - http://www.scopus.com/inward/record.url?scp=77955440435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955440435&partnerID=8YFLogxK

U2 - 10.1021/pr1005263

DO - 10.1021/pr1005263

M3 - Article

C2 - 20568814

AN - SCOPUS:77955440435

VL - 9

SP - 4228

EP - 4233

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 8

ER -